Large-scale Clinical-grade Retroviral Vector Production in a Fixed-Bed Bioreactor

Xiuyan Wang,* † Malgorzata Olszewska,† Jinrong Qu,* Teresa Wasielewska,* Shirley Bartido,* Gregory Hermetet,‡ Michel Sadelain,†§ and Isabelle Riviere* †§

Summary: The successful genetic engineering of patient T cells with γ-retroviral vectors expressing chimeric antigen receptors or T-cell receptors for phase II clinical trials and beyond requires the large-scale manufacture of high-titer vector stocks. The production of retroviral vectors from stable packaging cell lines using roller bottles or 10- to 40-layer cell factories is limited by a narrow harvest window, labor intensity, open-system operations, and the requirement for significant incubator space. To circumvent these shortcomings, we optimized the production of vector stocks in a disposable fixed-bed bioreactor using good manufacturing practice–grade packaging cell lines. High-titer vector stocks were harvested over 10 days, representing a much broader harvest window than the 3-day harvest afforded by cell factories. For PG13 and 293Vec packaging cells, the average vector titer and the vector stocks’ yield in the bioreactor were higher by 3.2- to 7.3-fold, and 5.6- to 13.1-fold, respectively, than those obtained in cell factories. The vector production was 10.4 and 18.6 times more efficient than in cell factories for PG13 and 293Vec cells, respectively. Furthermore, the vectors produced from the fixed-bed bioreactors passed the release test assays for clinical applications. Therefore, a single vector lot derived from 293Vec is suitable to transduce up to 500 patients cell doses in the context of large clinical trials using chimeric antigen receptors or T-cell receptors. These findings demonstrate for the first time that a robust fixed-bed bioreactor process can be used to produce γ-retroviral vector stocks scalable up to the commercialization phase.

Key Words: scalable clinical-grade vector manufacture, γ-retroviral vector, fixed-bed bioreactor, high vector titers, high vector yields

(J Immunother 2015;38:127–135)

Generation of large-scale, high-titer, clinical-grade retroviral vector stocks under current good manufacturing practice is a prerequisite for the implementation of phase I/II clinical trials using cell engineering approaches. Previous studies from our laboratory established a large-scale clinical-grade retroviral vector production platform using 10-layer cell factories,¹ which currently supports multiple phase I clinical trials.² ³ ⁴ Nonetheless, limitations in incubator space and the number of 10-layer cell factories that operators can handle per production run renders further scaling up difficult. In addition, the optimal harvest window for vector stocks in 10 tray-cell factories is confined to 3 days due to the rapid decline of vector titer in static culture. To overcome those limitations and to meet the increasing demand for clinical-grade vector stocks, it is imperative to establish new vector production platforms that are robust, scalable, and practical to handle.

The Pall iCELLis nano system is a scalable, disposable bioreactor that combines the advantages of single-use technologies with those of a fixed-bed. Its compact design not only eliminates the need for microcarriers, but also the requirement for a large footprint. Moreover, it allows the initiation of a perfusion mode whenever needed. The fixed-bed is packed with custom microfiber carriers which allows the biomass immobilized on the carrier to grow to a very high cell density. A built-in magnetic drive impeller facilitates the circulation of culture medium. Culture media passes through the bedding in the upward direction and falls as a thin-film down the outer wall of the fixed-bed where it takes up oxygen that is fed into the bioreactor. The levels of CO₂, oxygen, and pH, as well as agitation speed and gas flow are continuously measured and recorded, and can be regulated through its multichannel controller. This fixed-bed bioreactor was originally developed to produce human and veterinary viral vaccines from MDBK and Vero cells as well as monoclonal antibodies (Pall, personal written communications). We therefore investigated this system for large-scale clinical-grade vector production using the 293Vec and PG13 vector producers and the characteristics of the viral vector stocks generated from 293Vec and PG13 producers were tested, in the 0.53 m² (40 mL C1 compaction), the 1.07 m² (40 mL C2 compaction), the 2.67 m² (200 mL C1 compaction), and the 5.33 m² (200 mL C2 compaction) bioreactors. We found that the 200 mL C1 bioreactor platform was 10 to 20 times more efficient than the 10-layer cell factories in the production of clinical-grade vectors. Moreover, the vector stocks generated from the fixed-bed bioreactors passed a range of release tests, allowing the qualification of these vector stocks for phase I/II clinical trials. The improved production efficiency and the safety profiles of the vector stocks produced in the fixed-bed bioreactor make this bioreactor a unique system for scalable clinical-grade vector production up to 30 L per run.
MATERIALS AND METHODS

Cells Lines and Culture Conditions

The PG13 packaging line was derived from a genetically engineered PG13 cell clone expressing an anti-CD19 chimeric antigen receptor (CAR). Both cell lines were derived from a genetically engineered 293Vec cell clone expressing anti-PSMA CAR. Both cell lines were maintained in Dulbecco’s modified Eagle’s medium (Life Technologies), containing 10% heat-inactivated fetal bovine serum (Gemini) and 2 mM of glutamine (Life Technologies).

iCELLis Nano Fixed-Bed Bioreactor Culture

The Pall Life Sciences iCELLis nano bioreactors, 40 mL C1, 40 mL C2, 200 mL C1, and 200 mL C2, were used in the configuration as proposed by the manufacturer. For the 40 mL C1 and 40 mL C2 bioreactors, a working volume of 800 mL in the bioreactor housing was used during testing. For the 200 mL C1 and the 200 mL C2 bioreactors, a working volume of 800 mL for the bioreactor housing was used for the first 2 to 3 days. An additional 2000 mL perfusion loop was connected to the system for a total of 2800 mL cultivation volume. All the bioreactors with microfiber fixed-bed were autoclaved before cell inoculation. The parameters for all our test runs were pH of 7.4, O2 at 50% air saturation, temperature of 37°C, an inoculation agitation of 1000 rpm for 5 hours, followed by a culture agitation of 800 to 850 rpm. These parameters were recorded and analyzed using the JUMO PCA and PCC program. The cell numbers in the fixed-bed bioreactors were determined daily by nuclei enumeration. Lactate levels were determined daily using Lactate Pro test strips and test meter (ARKRAY Inc., Kyoto, Japan). Glucose levels were determined using an Accu-Chek blood glucose testing system (Roche Diagnostics, Indianapolis, IN).

Cell Number Determination

The number of cells attached to the microfibers was determined daily by counting cell nuclei using crystal violet staining after cell lysis. Briefly, 2 microfiber carrier strips from the top of the fixed-bed were taken out and lysed with 0.5 mL lysis buffer A for 1 minute. The reaction was stopped by adding 0.5 mL of stabilizing buffer B (Chemometec). Nuclei from the lysed cells were counted using a hemocytometer.

Staining of the Cells Attached to the Microfibers

Microfiber strips taken from the top of the fixed-bed were incubated with 0.4% crystal violet in 20% ethanol for 2 minutes and then rinsed in deionized water once. Images of the cells on the microfibers were taken using Nikon Microscope and camera.

Endotoxin Detection

Endotoxin levels were determined in the last harvest of the viral vector stocks derived from the 293Vec and the PG13 packaging cells in the runs performed with the iCELLis Nano 200 mL C1 bioreactors. The FDA-approved Endosafe Portable Test System (Charles River Laboratories) was used according to the manufacturer’s recommendations.

Rapid Mycoplasma Testing

Mycoplasma detection was performed on the last harvest of viral vector stocks derived from the 293Vec and the PG13 packaging cell lines in the test runs performed with the iCELLis Nano 200 mL C1 bioreactors using the MycoAlert Mycoplasma Detection Kit, following manufacturer’s recommendations (Cambrex).

T-cell Transduction

T cells selected and activated with CD3/CD28 Dynabeads (Invitrogen) from healthy donors were transduced with vector stocks harvested from iCELLis Nano bioreactors or cell factories at various dilutions using T cells at 1 × 10^6 per mL. Transduction efficiency was determined by FACS analysis using FITC conjugated anti-CD3 (invitrogen), biotin-conjugated goat anti-mouse antibody followed by PE-labeled streptavidin (Becton Dickinson) for CAR.

Determination of Vector Titer by Real-Time Polymerase Chain Reaction Analysis

Genomic DNA was extracted from transduced T cells. Quantification of the SFG-1928z vector copy number (from PG13 packaging cells) or SFG-TP28z vector copy number (from 293Vec packaging cells) was determined by real-time polymerase chain reaction as previously described. Titers of the vector stocks were calculated using the following formulation. Vector titer = Vector copy number × Number of cells at time of transduction × Dilution factor of the vector/volume of culture at time of transduction.

Detection of Gibbon Ape Leukemia Virus Envelope by PCR for Testing of RCR

The presence of DNA sequences encoding the gibbon ape leukemia virus (GaLV) envelope was tested in the genomic DNA extracted from T lymphocytes transduced with the final harvests of the 200 mL C1 bioreactors for both 293Vec and PG13 packaging cell lines. The primer sequences specific for the GaLV envelope, and the positive control for this method was the same as previously described.

Southern Blot Analysis

10 μg of Genomic DNA extracted from untransduced T lymphocytes or T lymphocytes transduced with vector stocks harvested from the 200 mL C1 bioreactors runs were digested with Nhe I endonuclease. A 32P-labeled probe specific for the vector sequence was prepared using a Random primer labeling system (GE), probes were subsequently purified using a Microspin G-50 column (GE). Southern blot analysis was performed using PerfectHyb hybridization buffer (Sigma) following manufacturer’s recommendations.

RESULTS

Comparison of the Fixed-Bed Bioreactor to Roller Bottles and 10-Layer Cell Factories

A range of surface areas, including 0.53 m² (40 mL Nano C1 compaction), 1.07 m² (40 mL C2 compaction), 2.67 m² (200 mL C1), and 5.33 m² (200 mL C2) depending on the fixed-bed volume and the custom carrier compaction level are available. The footprint of the fixed-bed bioreactors is the same regardless of the various fixed-bed volumes and compaction levels with a docking footprint of 200 × 120 × 200 mm (D × H × W). The 200 mL C2 bioreactor has a surface area equivalent to 64 roller bottles (850 mL) and 8.5 ten-layer cell factories (CF-10) (Table S1,
Growth of 293Vec and PG13 Packaging Cells in Fixed-Bed Bioreactors

To investigate the usage of the fixed-bed bioreactors for retroviral vector production, we first tested the growth of 293Vec packaging cells in the 40 mL C1 bioreactor using 800 mL of working volume without a perfusion loop. 293Vec cells were inoculated at 50,000 cells/cm² with an agitation rate of 1000 rpm during the inoculation phase, followed by an agitation rate of 800 rpm during the cultivation phase. Cells were batch-fed daily with 800 mL of fresh medium. Samples were taken from the bioreactor to determine glucose and lactate levels on a daily basis. The number of cells attached to the microfibers was determined by nuclei enumeration as described in the Materials and methods section. The number of cells that did not attach to the microfibers was determined in the cultivation media by trypan blue exclusion. The 293Vec packaging cells showed continuous growth during the 10-day culture period. More than 99% of the cells were attached to the microfibers, whereas <1% of the cells were detected in suspension. 293Vec packaging cells reached a cell density of 560,000 cells/cm² in the 40 mL C1 bioreactor by day 10 (Fig. 1A). We subsequently tested the same 293Vec cell line in the 200 mL C1 bioreactor under the same conditions, except for the addition of a 2000 mL perfusion loop starting on day 3. We found that the growth of 293Vec packaging cells in the 200 mL C1 bioreactor was even more robust. Cell density reached 975,000/cm² on day 10 and 1,180,000 cells/cm² by the end of the testing on day 11 (Fig. 1A).

Encouraged by the results with the 293Vec cell line, we tested the PG13 packaging cell line in the 40 mL C2, 200 mL C1, and 200 mL C2 bioreactors. A perfusion loop was added on day 2 for the 200 mL C1 and 200 mL C2 bioreactors, but not for the 40 mL C2 bioreactor. The 40 mL C2 bioreactor has twice the microfiber content as the 40 mL C1 bioreactor, and thus provides a surface area of 1.07 m², with the same 2 cm fixed-bed height. In the 40 mL C2 bioreactor, the PG13 packaging cell line showed continuous growth during the 9-day culture period and reached 400,000 cells/cm² at day 8 (Fig. 1B). We next tested the PG13 packaging cell line in 200 mL C1 bioreactor. Because of a lack in oxygen supply during the 200 mL C1 run on day 2 and day 3 of the culture (Fig. S1B, Supplemental Digital Content 1, http://links.lww.com/JIT/A367), the cell growth of the PG13 cells was delayed from day 5 to day 8. However, the cell growth subsequently recovered, and cell density reached 421,000 cells/cm² by day 10 (Fig. 1B). We further tested the 200 mL C2 bioreactor using PG13 packing cells line. The 200 mL C2 bioreactor has twice the microfiber content compared with the 200 mL C1 bioreactor with the same 10 cm fixed-bed height, which gives a total surface area of 5.33 m² (Table S1, Supplemental Digital Content 2, http://links.lww.com/JIT/A368). We hypothesized that the

![Graph](image-url)
Comparison of Large-scale Clinical-grade Vector Production in 200 mL C1 Bioreactor and in Six 10-Layer Cell Factories

To further evaluate the feasibility of large-scale clinical-grade vector production using the 200 mL C1 bioreactor, we harvested the viral vector stocks from the 200 mL C1 PG13 and the 293Vec packaging runs described previously on a daily basis for titration and release testing purposes. The experimental parameter settings, including time, pH, CO2, and O2 levels, agitation speeds, and gas flow were all digitally recorded during the entire runs with the multichannel process controller. The run for the 293Vec packaging cell run smoothly as indicated in Figure S1A (Supplemental Digital Content 1, http://links.lww.com/JIT/A367). However, we encountered a problem with the PG13 packaging cell line. The run for the 293Vec 200 mL C1 run, and from 2 to 23 mM in the PG13 200 mL C1 run, whereas glucose in the medium was rapidly consumed (data not shown). These observations demonstrated that both PG13 and 293Vec packaging cells tolerated high lactate concentration and observations demonstrated that both PG13 and 293Vec the medium was rapidly consumed (data not shown). These findings suggest that the compaction factor of 2 was too high and prevented the distribution of the cells in the bioreactor with the inoculation agitation speed of 1000 rpm. As higher agitation speed would result in high shear stress on cells, which was not recommended by the manufacturer, we therefore focused on the 200 mL C1 bioreactors.

In line with rapid increase of cell density for both PG13 and 293Vec cell lines in the 200 mL C1 bioreactors, crystal violet staining of the microfibers sampled from the bioreactor showed expansion of the cells in the junctions between fibers (Fig. 1D). The lactate level increased rapidly from 2 to 19 mM in the 293Vec 200 mL C1 run, and from 2 to 23 mM in the PG13 200 mL C1 run, whereas glucose in the medium was rapidly consumed (data not shown). These observations demonstrated that both PG13 and 293Vec packaging cells tolerated high lactate concentration and that the 200 mL C1 bioreactor could support optimal cell growth.

Stability of the Vector Stocks Upon Long-term Storage

Our laboratory and others previously demonstrated that vector stocks generated in the 10-layer cell factories are stable up to 3 to 9 years at –80°C.1,10 We tested the stability of the vector stocks derived from PG13 cells after 1 year of storage and after 10 months of storage for the 293Vec packaging cells. Harvests 3, 6, 9, and 10 from 293Vec cells and harvests 4, 7, 9, and 10 from PG13 cells were titrated on primary T lymphocytes. All the vector stocks harvested containing 10% of serum maintained the same titer (Figs. 2C, D). However, the titer of the vector stocks harvested in serum-free medium decreased. At the dilution factor of 4 (vol/vol) corresponding to a multiplicity of infection (MOI) of 0.04 to 0.79, the transduction efficiency of serum-free harvest 8 (H8*) and harvest 10 (H10*) from PG13 cells was much lower than that of the same vector stocks before storage at –80°C (Fig. 2D). Only at a lower dilution factor of 2, the transduction efficiency of the serum-free vector stocks was comparable to that of the same vector before storage (Fig. 2E). Therefore, the titer of the serum-free
vector dropped approximately 50% after 1-year storage, suggesting that the serum-free vector stocks are less stable than the serum-containing vector stocks.

Stability of the Vector Stocks Upon Multiple Freeze and Thaw Cycles

Previous studies showed that the half-life of the GaLV-enveloped vector was approximately 7.5 hours in DMEM with 10% serum at 37°C and about 54 hours at 4°C. An alternative approach to 4°C storage of the viral stocks was therefore needed during the 10-day harvest of the vector stocks from the 200 mL C1 bioreactor. To this end, we tested the stability of the vector stocks harvested with serum-containing medium upon multiple freeze and thaw cycles. After an additional freeze and thaw cycle, we observed a modest 16% decrease of the titer of the vector stocks derived from the 293Vec packaging cell line, whereas a more dramatic decrease of 53% of the titer of vector stocks derived from the PG13 packaging cell line was found (Fig. 2F). The titer of the vector stocks derived from the 293Vec cells is much higher than that of the PG13 cells (Tables 1 and 2), suggesting that vector stocks with higher initial titers are more resilient to repeated freeze and thaw cycles. Alternatively, vectors stocks produced in the human 293Vec packaging cells may be more stable during cryopreservation than stocks derived from the murine PG13 packaging cells.

Vector Stocks Derived From Fixed Bioreactors are Qualitatively Equivalent to Vector Stocks Derived From Cell Factories

To demonstrate the suitability of the fixed-bed bioreactor for the production of clinical-grade vector stocks, we performed an array of release tests on the final harvests of each of the 200 mL C1 bioreactor runs for the 293Vec cells.
TABLE 1. Comparison of Vector Production Yields Derived From 293Vec Cells Using Either 200 mL C1 Bioreactor or Six 10-Layer Cell Factories

| Inoculation Cell Density | iCELLis 200 mL C1 | 6 CF-10 |
|--------------------------|------------------|--------|
| Total Surface Area (cm²) | 3.9×10⁴/cm²      | 8.3×10⁴/cm² |

| Vector Stocks Volume/Harvest | 800 mL for H1 and H2; 2800 mL for H3 to H10 |
|-----------------------------|---------------------------------------------|
| Harvest #/days Postinoculation | Titer TCIU/mL | Yield of Each Harvest | Titer TCIU/mL | Yield of Each Harvest |
| Harvest 1/day 2 | 2.76×10⁷ | 2.21×10¹⁰ | 1.95×10⁷ | 7.03×10¹⁰ |
| Harvest 2/day 3 | 9.23×10⁷ | 7.38×10¹¹ | 1.67×10⁷ | 6.00×10¹⁰ |
| Harvest 3/day 4 | 8.19×10⁷ | 2.29×10¹¹ | 1.73×10⁷ | 6.24×10¹⁰ |
| Harvest 4/day 5 | 1.35×10⁸ | 3.77×10¹¹ | NA | NA |
| Harvest 5/day 6 | 1.40×10⁸ | 3.93×10¹¹ | NA | NA |
| Harvest 6/day 7 | 1.31×10⁸ | 3.68×10¹¹ | NA | NA |
| Harvest 7/day 8 | 1.18×10⁸ | 3.30×10¹¹ | NA | NA |
| Harvest 8/day 9 | 9.09×10⁷ | 2.54×10¹¹ | NA | NA |
| Harvest 9/day 10 | 8.90×10⁷ | 2.49×10¹¹ | NA | NA |
| Harvest 10/day 11 | 8.48×10⁷ | 2.37×10¹¹ | NA | NA |
| Total volume harvested (L) | 24 | 10.8 |
| Total vector yield | 2.53×10¹² | 1.93×10¹¹ |

*Harvest 9 and 10 are serum-free vector stocks.

Primary T cells derived from a healthy donor were transduced with vector stocks harvested from 293Vec cells at dilutions of 1:3, 1:9, and 1:27. Genomic DNA was extracted from the transduced T cells and subjected to vector-specific real-time qPCR analysis to determine the vector copy number (VCN). Titer of the vector was calculated according to the following formula: vector titer = VCN × number of T cells at time of infection ÷ dilution factor of the vector/volume of cell culture at time of transduction. Yield of each harvest = titer of the vector harvest (TCIU/mL) × volume of the harvest (mL).

TABLE 2. Comparison of Vector Production Yields Derived From PG13 Cells Using Either 200 mL C1 Bioreactor or Six 10-Layer Cell Factories

| Inoculation Cell Density | iCELLis 200 mL C1 | 6 CF-10 |
|--------------------------|------------------|--------|
| Total Surface Area (cm²) | 4.89x10⁴/cm²      | 4.93x10⁴/cm² |

| Vector Stocks Volume/Harvest | 800 mL for H1 and H2; 2800 mL for H3 to H10 |
|-----------------------------|---------------------------------------------|
| Harvest #/days Postinoculation | Titer TCIU/mL | Yield of Each Harvest | Titer TCIU/mL | Yield of Each Harvest |
| Harvest 1/day 1 | 7.99×10⁵ | 6.39×10⁸ | 1.70×10⁷ | 6.12×10⁸ |
| Harvest 2/day 2 | 8.66×10⁵ | 6.93×10⁸ | 4.90×10⁵ | 1.76×10⁸ |
| Harvest 3/day 3 | 1.58×10⁵ | 4.42×10⁹ | 4.40×10⁵ | 1.58×10⁹ |
| Harvest 4/day 4 | 1.40×10⁶ | 3.92×10⁹ | NA | NA |
| Harvest 5/day 5 | 3.16×10⁶ | 8.82×10⁹ | NA | NA |
| Harvest 6/day 6 | 1.82×10⁶ | 5.10×10⁹ | NA | NA |
| Harvest 7/day 7 | 1.91×10⁶ | 3.33×10⁹ | NA | NA |
| Harvest 8/day 9 | 7.45×10⁶ | 2.09×10¹⁰ | NA | NA |
| Harvest 9*/day 10 | 7.88×10⁶ | 2.21×10¹⁰ | NA | NA |
| Harvest 10*/day 11 | 6.47×10⁶ | 1.81×10¹⁰ | NA | NA |
| Total volume harvested (L) | 24 | 10.8 |
| Total vector yield | 2.90×10¹⁰ | 3.96×10⁹ |
TABLE 3. Release Tests Performed on the Last Harvest of the Vector Stocks Derived From 293Vec and PG13 Cells Produced in the 200 mL C1 Bioreactor

| Tests                                           | Methods                      | Specification                  | 293Vec Harvest 10 | PG13 Harvest 10 |
|------------------------------------------------|------------------------------|--------------------------------|--------------------|-----------------|
| Viral titer (bulk supernatant) (TCIU/ml)        | Endpoint titration on T cells| Report results                 | $8.48 \times 10^7$ TCIU/mL | $6.47 \times 10^5$ TCIU/mL |
| Final product sterility (final-filled containers) | 21 CFR 610.12 membrane-filtration | No growth at 14 days           | No growth at 14 days          | No growth at 14 days |
| Final product bacterial endotoxin (final-filled containers) | Kinetic chromogenic LAL assay | $< 10$ EU/mL                    | $< 1$ EU/mL               | $< 1$ EU/mL               |
| Bulk sterility (EOP supernatant)                | 21 CFR 610.12 membrane-filtration | No growth at 14 days           | No growth at 14 days          | No growth at 14 days |
| Mycoplasma (EOP supernatant)                    | Cell lines PTC               | Negative                        | No mycoplasma             | No mycoplasma             |
| GaLV replication-competent retrovirus testing   | Marker-rescue cell culture assay | No RCR detected                | ND                  | No RCR detected       |

ND indicates not done.

FIGURE 3. GaLV RCR assay using PCR and vector integrity assay by Southern blot analysis. A, Genomic DNA extracted from untransduced or transduced T lymphocytes were examined for the GaLV envelope using specific primers for PCR as previously described. Lanes 1 and 13, 100 bp DNA ladder; lanes 2 and 7, no template control; lanes 3 and 8, 5 and 10, untransduced T cells (UT); lanes 4 and 9, transduced with harvest 10 derived from 293Vec cells (SFG-TP28z vector); lanes 6 and 11, transduced with harvest 10 derived from PG13 cells (SFG-1928z vector); lane 12: positive control (6 copies GaLV env plasmid). B, Genomic DNA extracted from untransduced or transduced T lymphocytes were digested and hybridized with $^{32}$P-labeled specific probes as described in material and methods. Lanes 1 and 4, 1 kb DNA ladder; lanes 2 and 5, untransduced T cells; lane 3, transduced T cells with harvest 10 derived from 293Vec cells (SFG-TP28z vector); lane 6, transduced T cells with harvest 10 derived from PG13 cells (SFG-1928z vector). Arrows indicate the expected integrated vector size.
DISCUSSION

Retroviral vectors are used in a large number of clinical trials for gene transfer-based adoptive cell therapies.\textsuperscript{2,13} It is therefore desirable to develop a robust platform for the production of vector stocks to support the increasing demand of clinical-grade vectors. In this study, we investigated the usage of a fixed-bed bioreactor for the generation of scalable clinical-grade vector stocks. The production efficiencies for both the 293Vec and the PG13 packaging cell lines are significantly increased in the 200 mL C1 bioreactor when compared with the six 10-layer cell factories. The 200 mL C1 bioreactor not only supported the production of higher titer vector stocks, but also extended the time window for vector harvesting (Tables 1 and 2). We observed a linear scalability when comparing the 40 mL C1 bioreactor to the 200 mL C1 bioreactor (Fig. 1A and data not shown). However, there was no linear scalability observed between the 200 mL 1C bioreactor and the 200 mL C2 bioreactor (Fig. 1B). The larger surface area gained by higher fiber density in the 200 mL C2 bioreactor was offset by the uneven distribution of cells (Fig. 1C), slower cell expansion (Fig. 1B), as well as a reduced vector harvest window, which resulted in decreased production efficiency (data not shown). More recently, bioreactors with compaction factor of 2 were discontinued and replaced with a bioreactor with compaction factor of 1.5. It will be of interest to test whether the C1.5 bioreactors outperform the C1 bioreactors in the context of our experimental settings. Nonetheless, we have demonstrated in this study that the 200 mL C1 bioreactor is a robust and economical vector production platform when compared with the 10-layer cell factories.

During our production runs, we observed a direct correlation between the oxygen level, the cell growth rate, and the vector titers. Disruption of the oxygen supply on day 2 during the PG13 production run in the 200 mL C1 bioreactor led to a transient 5-fold decrease in vector titer on day 3 (Table 2) concomitant with a delay in cell expansion (Fig. 1B). It is interesting to note that, the cell growth and the vector titer recovered shortly after restoration of the oxygen supply. These observations emphasize the importance of maintaining optimal oxygen level in the generation of high-titer vector stocks. The real-time monitoring of the critical parameters by the bioreactor controller made it possible to identify and resolve potential problems in a timely fashion.

To address the intrinsic short half-life of the GalV-envelope\textsuperscript{11,14} and the broad harvest window of 10 days, we tested the effect of 2 rounds of freeze-thaw cycles on vector titer. A modest drop of 16% in vector titer was observed for high-titer vector stocks derived from the 293Vec packaging cell line, whereas a more profound 53% drop in vector titer was observed for the relatively lower titer vector stocks generated from the PG13 packaging cell line (Fig. 2F, Tables 1 and 2). As the vectors produced from the 293Vec and the PG13 cells are both pseudotyped with the GalV-envelope\textsuperscript{9,15} and express vectors with similar design and size\textsuperscript{7,8} our results strongly suggest that higher titer vector stocks are more stable upon freeze-thaw. It is also possible that the human 293 membrane components of the virions may be sturdier than their counterparts derived from the murine PG13 cells. Nonetheless, given the fact that vector stocks from both 293Vec and PG13 cells passed the required release tests, the 293Vec cells appear to be the packaging cell line of choice based upon its higher vector titer (Table 3, Fig. 2).

Merten and colleagues have compared different bioreactor systems, such as the CellCube system, the Fibra-Cel fixed-bed basket reactor, and the Cytodex beads stir-tank Celllift reactor. This group also reported that the Fibra-Cel fixed-bed basket reactor system demonstrates the highest productivity.\textsuperscript{14} It will be interesting to compare the Fibra-Cel fixed-bed system and the Pall Life Sciences iCELLis system in our experimental setting. The iCELLis bioreactor presents the advantage of scalability. Commercial scale bioreactors with surface areas of 66 to 500 m\textsuperscript{2} are available in a small footprint with real-time process control.

On the basis of our results, we are designing a production and harvest scheme for the manufacturing of large-scale clinical-grade retroviral vectors using the 200 mL C1 bioreactor (Fig. S2, Supplemental Digital Content 3, http://links.lww.com/JIT/A69). To initiate vector manufacturing, a vial of cells is thawed and passaged in T flasks until sufficient number of cells are accumulated to inoculate the 200 mL bioreactor (1 to 2 passages). Cells in the bioreactor are batch-fed with 800 mL of medium for 2 days with perfusion starting from day 2 with an additional 2000 mL of medium. The cells are subsequently batch-fed with a total of 2800 mL from day 3 to day 11. Viral stocks are collected on a daily basis and stored at \(-80^\circ\text{C}\). After determining the vector titer, high-titer vector harvests are pooled and aliquoted in suitable-sized cryo-containers. On the basis of our current CAR T-cell manufacturing process,\textsuperscript{2,6,16} a single vector lot derived from either PG13 or 293Vec manufactured in the 200 mL C1 bioreactor is suitable to transduce at least 70 to 500 patient T-cell doses, respectively. This scale is amply sufficient for most phase I and II clinical trials. Our results further suggest that the industrial scale of these bioreactors with surface areas of 66 to 500 m\textsuperscript{2} could accommodate vector production for thousands of patients as required for the commercialization phase of genetically modified T cells expressing either CARs or T-cell receptors.

Many important parameters are involved in vector production, such as the choice of packaging cell line,\textsuperscript{17,18} vector design,\textsuperscript{19,20} type of bioreactor,\textsuperscript{14} medium additives,\textsuperscript{21} serum concentration,\textsuperscript{22,23} temperature,\textsuperscript{15,24} perfusion rate during the cultivation,\textsuperscript{14} and timing for vector harvest.\textsuperscript{15} Our data demonstrate for the first time that the Pall Life Sciences iCELLis fixed-bed bioreactor is a robust platform for scalable clinical-grade retroviral vector production. Ongoing studies will build upon the iCELLis bioreactor experience to identify other important parameters for optimizing large-scale clinical-grade retroviral vector production, such as vector production in serum-free media or with serum replacement supplement, as well as the addition of stabilizing agents that would increase the stability of vector stocks harvested in serum-free media. The implementation of and further improvements to this platform will ease the process and reduce the cost of manufacturing genetically modified cells for adoptive cell therapy applications.

ACKNOWLEDGMENTS

The authors thank Matt Kremer at Pall Life Sciences for providing MSKCC the opportunity to test the iCELLis Nano bioreactors in the context of this application. They also thank Manuel Caruso (Université Laval, QC) for providing the 293Vec parental cell line.
The authors also thank Matt Kremer and Mark Bonyhadi for critically reviewing the manuscript.

CONFLICT OF INTERESTS/FINANCIAL DISCLOSURES

Supported by the NCI P30 CA08748, P50 CA086438 and Starr Foundation Tri-Institutional Stem Cell Initiative.
I.R. is a scientific cofounder of Juno Therapeutics and a consultant for Juno Therapeutics. All the remaining authors have declared that there are no financial conflicts of interest with regard to this work.

REFERENCES

1. Przybylowski M, Hakakha A, Stefanski J, et al. Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories. *Gene Therapy*. 2006;13:95–100.
2. Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. *Blood*. 2011;118:4817–4828.
3. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. *Sci Transl Med*. 2013;5:177ra138:1–9.
4. Davila ML, Bouhassira DC, Park JH, et al. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. *Int J Hematol*. 2014;99:361–371.
5. Miller AD, Garcia JV, von Suher N, et al. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. *J Virol*. 1991;65:2220–2224.
6. Hollyman D, Stefanski J, Przybylowski M, et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. *J Immunother*. 2009;32:169–180.
7. Brentjens RJ, Santos E, Nikhaim Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. *Clin Cancer Res*. 2007;13:5426–5435.
8. Maher J, Brentjens RJ, Gunset G, et al. Human T-lymphocyte cytoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. *Nat Biotechnol*. 2002;20:70–75.
9. Ghani K, Wang X, de Campos-Lima PO, et al. Efficient human hematopoietic cell transduction using RD114- and GALV-pseudotyped retroviral vectors produced in suspension and serum-free media. *Hum Gene Ther*. 2009;20:966–974.
10. Lamers CH, van Elzakker P, Luider BA, et al. Retroviral vectors for clinical immunogene therapy are stable for up to 9 years. *Cancer Gene Ther*. 2008;15:268–274.
11. Schilz AJ, Kuhlcke K, Fauser AA, et al. Optimization of retroviral vector generation for clinical application. *J Gene Med*. 2001;3:427–436.
12. Suerth JD, Schambach A, Baum C. Genetic modification of lymphocytes by retrovirus-based vectors. *Curr Opin Immunol*. 2012;24:598–608.
13. Rivat C, Santilli G, Gaspar HB, et al. Gene therapy for primary immunodeficiencies. *Hum Gene Ther*. 2012;23:668–675.
14. Merten OW, Cruz PE, Rochette C, et al. Comparison of different Bioreactor systems for the production of high titer retroviral vectors. *Biotechnol Prog*. 2001;17:326–335.
15. Reeves L, Smucker P, Cornetta K. Packaging cell line characteristics and optimizing retroviral vector titer: the National Gene Vector Laboratory experience. *Hum Gene Ther*. 2000;11:2093–2103.
16. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. *Sci Transl Med*. 2014;6:224ra225:1–10.
17. Rigg RJ, Chen J, Dando JS, et al. A novel human amphotropic packaging cell line: high titer, complement resistance, and improved safety. *Virology*. 1996;218:290–295.
18. Forestell SP, Dando JS, Chen J, et al. Novel retroviral packaging cell lines: complementary tropisms and improved vector production for efficient gene transfer. *Gene Ther*. 1997;4:600–610.
19. Palu G, Parolin C, Takeuchi Y, et al. Progress with retroviral gene vectors. *Rev Med Virol*. 2000;10:185–202.
20. Mangeot PE, Negre D, Dubois B, et al. Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells. *J Virol*. 2000;74:8307–8315.
21. Olsen JC, Sechelski J. Use of sodium butyrate to enhance production of retroviral vectors expressing CFTR cDNA. *Hum Gene Ther*. 1995;6:1195–1202.
22. Shen BQ, Clarke MF, Palsson BO. Kinetics of retroviral production from the amphotropic PsiCRIP murine producer cell line. *Cytotechnology*. 1996;22:185–195.
23. Gerin PA, Gilligan MG, Searle PF, et al. Improved titers of retroviral vectors from the human FLYRD18 packaging cell line in serum- and protein-free medium. *Hum Gene Ther*. 1999;10:1965–1974.
24. McGaugh M, Al-Rubeai M. Effects of culture parameters on the production of retroviral vectors by a human packaging cell line. *Biotechnol Prog*. 2000;16:859–865.